

Severe Hypoglycemia – Pipeline Insight, 2020

<https://marketpublishers.com/r/S5C020F46352EN.html>

Date: November 2020

Pages: 80

Price: US\$ 2,500.00 (Single User License)

ID: S5C020F46352EN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Severe Hypoglycemia – Pipeline Insight, 2020," report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Severe Hypoglycemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Severe Hypoglycemia Understanding

Severe hypoglycemia: Overview

Hypoglycemia is a common side effect of diabetes therapy, resulting in a lack of adequate cerebral glucose supply, leading to a range of neurogenic and neuroglycopenic symptoms, which in turn can lead to death, if not treated on time. Intensive glycemic control significantly increases the risk of hypoglycemia in patients with diabetes mellitus. Severe hypoglycemia is a high-risk state and is followed by a high rate of cardiovascular events and deaths in persons with diabetes.

Symptoms

The symptoms of Severe Hypoglycemia include:

Neurogenic (autonomic)- Trembling Palpitations Sweating Anxiety Hunger
Nausea Tingling

Neuroglycopenic- Difficulty concentrating Confusion, weakness, drowsiness,
vision changes Difficulty speaking, headache, dizziness

Diagnosis

Structured educational and psycho-behavioural programs (e.g. BG awareness training) may help improve detection of hypoglycemia and reduce the frequency of severe hypoglycemia.

Treatment

The goals of treatment for hypoglycemia are to detect and treat a low BG level promptly by using an intervention that provides the fastest rise in BG to a safe level, to eliminate the risk of injury and to relieve symptoms quickly. It is also important to avoid overtreatment since this can result in rebound hyperglycemia and weight gain. Glucose gel is quite slow and must be swallowed to have a significant effect. People taking an alpha glucosidase inhibitor (acarbose) must use glucose (dextrose) tablets or, if unavailable, milk or honey to treat hypoglycemia. Islet cell transplantation, which has been shown to reduce hypoglycemia and restore glucose counter-regulation, should be considered for people with type 1 diabetes who experience recurrent severe hypoglycemia.

Severe Hypoglycemia Emerging Drugs Chapters

This segment of the Severe Hypoglycemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Severe Hypoglycemia Emerging Drugs

NN9513: Novo Nordisk

NN9513 is an experimental drug that is a glucagon receptor agonists. The developer of NN9513 is Novo Nordisk and is currently in Phase I of the clinical trial.

Recombinant Human glucagon: Adocia

Recombinant Human glucagon is a Phase I glucagon receptor agonist in development for the treatment of Hypoglycemia. Using the BioChaperone technology, Adocia aims to develop a stable aqueous solution of recombinant human glucagon. As rhG is very unstable in aqueous solution, the only products commercially available today are emergency kits composed of lyophilized rhG to be reconstituted just before injection, following several steps.

Further product details are provided in the report.....

Severe Hypoglycemia: Therapeutic Assessment

This segment of the report provides insights about the different Severe Hypoglycemia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Severe Hypoglycemia There are approx. 30+ key companies which are developing the therapies for Severe Hypoglycemia. Majority of the drugs are in the early phases of trial.

Phases

DelveInsight's report covers around 30+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Severe Hypoglycemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Severe Hypoglycemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Severe Hypoglycemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Severe Hypoglycemia drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Severe Hypoglycemia R&D. The therapies under development are focused on novel approaches to treat/improve Severe Hypoglycemia

Severe Hypoglycemia Report Insights

Severe Hypoglycemia Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Severe Hypoglycemia Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Severe Hypoglycemia drugs?

How many Severe Hypoglycemia drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Severe Hypoglycemia?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Severe Hypoglycemia therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Severe Hypoglycemia and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Adocia

Novo Nordisk

Zucara Therapeutics

Key Products

Recombinant human glucagon

NN9513

Somatostatin type 2 receptor antagonists

Contents

- Introduction
- Executive Summary
- Severe Hypoglycemia: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Severe Hypoglycemia – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
 - Severe Hypoglycemia companies’ collaborations, Licensing, Acquisition -Deal Value
- Trends
 - Severe Hypoglycemia Collaboration Deals
 - Company-Company Collaborations (Licensing / Partnering) Analysis
 - Company-University Collaborations (Licensing / Partnering) Analysis
- Mid Stage Products (Phase II)
 - Comparative Analysis
- RZ358: XOMA
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I)
 - Comparative Analysis
- NN9513: Novo Nordisk
 - Product Description
 - Research and Development
 - Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Somatostatin type 2 receptor antagonist: Zucara Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Severe Hypoglycemia Key Companies

Severe Hypoglycemia Key Products

Severe Hypoglycemia - Unmet Needs

Severe Hypoglycemia - Market Drivers and Barriers

Severe Hypoglycemia - Future Perspectives and Conclusion

Severe Hypoglycemia Analyst Views

Severe Hypoglycemia Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Severe Hypoglycemia
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Severe Hypoglycemia
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Severe Hypoglycemia – Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/S5C020F46352EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S5C020F46352EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970